Lead Product(s): DSP-1181
Therapeutic Area: Psychiatry/Psychology
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
Through this deal, Sumitomo Dainippon Pharma has expanded its development pipeline to treat key unmet medical needs in the Psychiatry and Neurology area.